+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (100 mg Type, Other), By Application (Plaque Psoriasis, Other), and Regional Forecast, 2026-2034
The global guselkumab injection market was valued at USD 1.80 Bn in 2025 and is estimated at USD 1.92 Bn in 2026. The market is projected to reach USD 3.20 Bn by 2034, representing a 6.6% CAGR during 2026–2034.
Guselkumab is an IL-23p19-targeting biologic whose commercial opportunity has expanded from plaque psoriasis and psoriatic arthritis into inflammatory bowel disease. FDA approval of a new indication on March 20, 2025, Health Canada approval for Crohn’s disease in July 2025 and current EMA labeling across psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease materially broaden the addressable treatment population.
The revenue model for this report is narrower than total manufacturer product sales. Johnson & Johnson reported USD 5.155 billion in worldwide TREMFYA sales for 2025, including USD 3.529 billion in the United States, but those figures span indications, formulations and geographic accounting that should not be assigned wholesale to the target injection market. They are used here only as a competitive-demand indicator.
Commercial growth depends on label breadth, treatment sequencing, payer access, physician familiarity and delivery convenience. The market also faces strong therapeutic-class competition from other biologics and advanced oral therapies, making comparative outcomes, safety, dosing burden and reimbursement central to share capture.
Source: FDA 2025 efficacy supplement approvals; Johnson & Johnson FY2025 results; EMA Tremfya; Health Canada NOC.
The study covers commercial guselkumab injection revenue across the report’s supplied type and application structure, with analysis by presentation type, primary application grouping and geography.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD billion |
| By Type | 100 mg Type; Other |
| By Application | Plaque Psoriasis; Other |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, South Korea, Australia, Singapore, Brazil, GCC countries and other major markets |
| Key Market Players | Janssen Biotech, Inc.; Janssen-Cilag International NV; Janssen Inc. |
The market includes guselkumab injection and directly associated injectable presentations sold for approved therapeutic use. Revenue is allocated to guselkumab injection rather than to the broader immunology drug market or to unrelated Johnson & Johnson products.
Manufacturer-reported TREMFYA sales are treated as a competitive indicator because they span multiple indications and presentations. They are not substituted for the report market size unless the relevant injection-market revenue boundary is explicitly disclosed.
FDA listed a March 20, 2025 TREMFYA new-indication approval, while Health Canada approved guselkumab for moderately to severely active Crohn’s disease on July 7, 2025. Each added indication creates new specialist prescriber groups and reimbursement pathways.
Johnson & Johnson reported USD 5.155 billion in worldwide TREMFYA product sales for 2025, up from USD 3.670 billion in 2024. The scale supports continued investment in evidence generation, market access and lifecycle expansion, while remaining broader than the report’s injection-market revenue boundary.
Biologic and advanced-therapy markets are heavily shaped by formularies, prior authorization, previous-treatment requirements and negotiated access. A clinically eligible patient does not automatically translate into immediate guselkumab revenue if payers favor another class or require step therapy.
Guselkumab competes against established biologics and oral therapies across psoriasis, psoriatic arthritis and inflammatory bowel disease. Commercial differentiation therefore depends on durability, safety, dosing convenience, route, comparative outcomes and payer positioning rather than mechanism alone.
Ulcerative-colitis and Crohn’s-disease approvals move guselkumab beyond dermatology and rheumatology into gastroenterology, increasing addressable demand and creating opportunities for new dosing presentations and infusion-to-subcutaneous treatment pathways.
Health Canada and Singapore approvals in 2025 included 200 mg/2 mL subcutaneous presentations. Higher-strength formats can support maintenance strategies that reduce administration complexity and strengthen differentiation across specialist settings.
EMA’s March 2026 product information includes plaque psoriasis in children and adolescents from age six years. Age expansion and additional presentations can create incremental volume while using an established brand and evidence base.
A franchise spanning dermatology, rheumatology and gastroenterology can benefit from common mechanism familiarity, integrated payer negotiations and shared safety experience, though each specialty retains distinct treatment algorithms and competitors.
Plaque psoriasis provided the initial large-scale use case for guselkumab, supporting physician familiarity, specialty-pharmacy infrastructure and long-term biologic experience before expansion into additional indications.
Psoriatic-arthritis use extends the molecule across joint and skin manifestations, where treatment decisions account for disease domains, prior biologics, comorbidities and patient preference.
Ulcerative colitis and Crohn’s disease introduce guselkumab into treatment pathways with multiple biologic and advanced oral options. Uptake depends on induction and maintenance efficacy, safety, route, prior-treatment history and reimbursement sequencing.
The 100 mg presentation remains central to long-standing subcutaneous use and provides the reference format around which many prescribers and specialty pharmacies built familiarity.
New 200 mg/2 mL subcutaneous formats approved in markets including Canada and Singapore expand administration options for inflammatory bowel disease and increase the revenue mix associated with higher-strength maintenance dosing.
Inflammatory bowel disease can involve infusion-based induction and subcutaneous maintenance depending on jurisdiction and label. That creates multiple care settings, reimbursement routes and procurement stakeholders within one product franchise.
The 100 mg injection segment represents the established commercial base built through plaque psoriasis and psoriatic arthritis. It benefits from long-standing physician familiarity, specialty-pharmacy workflows and broad regulatory experience.
Other presentations include newer strengths and delivery configurations that support expanded indications and maintenance regimens. These formats are gaining strategic importance as guselkumab extends into inflammatory bowel disease and additional age groups.
The type mix is expected to become more diversified as higher-strength and indication-specific presentations gain volume alongside the established 100 mg base.
Plaque psoriasis remains a core application because guselkumab has an established efficacy and safety profile in systemic-treatment candidates and a mature prescribing infrastructure. Growth is more replacement- and share-driven than purely new-market creation.
Other applications include psoriatic arthritis, ulcerative colitis, Crohn’s disease and jurisdiction-specific indications. This segment is strategically important because recent label expansion materially increases the addressable patient pool and specialty prescriber base.
Application growth is expected to shift progressively toward newer inflammatory-bowel and lifecycle indications while plaque psoriasis remains a durable commercial foundation.
Regional performance reflects label timing, biologic penetration, payer access, specialty infrastructure and the manufacturer’s commercial footprint. Country signals are included only where regulatory or product-sales evidence materially clarifies market position.
North America is the largest regional market, led by the United States. High biologic utilization, large specialty-pharmacy networks, strong commercial investment and new inflammatory-bowel indications support value, while payer controls remain a major determinant of realized uptake.
Johnson & Johnson reported USD 3.529 billion in U.S. TREMFYA product sales in 2025, compared with USD 1.626 billion internationally. FDA also listed a new-indication approval on March 20, 2025, reinforcing the U.S. as the principal commercial anchor.
Source: Johnson & Johnson FY2025 results.
Health Canada issued a Notice of Compliance on July 7, 2025 for Crohn’s disease and new TREMFYA presentations, including 200 mg/2 mL subcutaneous formats. The update broadened both indication coverage and delivery options.
Source: Health Canada.
Europe combines broad EMA authorization with country-specific health-technology assessment and reimbursement. Dermatology, rheumatology and gastroenterology access can differ by national sequencing rules, so clinical approval does not produce uniform commercial penetration across the region.
EMA product information updated 23 March 2026 lists adult plaque psoriasis, pediatric plaque psoriasis from age six, psoriatic arthritis, ulcerative colitis and Crohn’s disease. The broad label supports cross-specialty commercial reach.
Source: European Medicines Agency.
NICE published technology appraisal TA1094 on 28 August 2025 for guselkumab in moderately to severely active ulcerative colitis, providing a defined health-technology-assessment pathway for NHS adoption.
Source: NICE.
Asia-Pacific offers a broad mix of mature biologic markets and faster-growing specialty-care systems. Commercial performance varies by regulatory timing, reimbursement, domestic pricing and specialist access, making country-specific label expansion a key leading indicator.
On 10 July 2025, Singapore HSA approved TREMFYA 200 mg infusion and 200 mg subcutaneous presentations with indications including plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease.
Source: Health Sciences Authority.
Latin American opportunity is concentrated in major private and public specialty-care markets. Biologic affordability, tendering, private insurance and specialist access can create significant differences between approved availability and treated-patient volume.
Gulf markets provide higher-value specialty biologic opportunities through well-funded healthcare systems, while many African markets face narrower reimbursement and specialist access. Distributor strength and payer coverage are therefore central to regional commercialization.
NICE published TA1094 for ulcerative colitis in August 2025. Formal appraisal pathways can materially affect prescribing volume because they determine eligible populations, sequencing and funded access within public health systems.
In the United States, biologic uptake depends on plan coverage, benefit design, prior authorization and treatment history. Manufacturer support and payer contracting therefore influence persistence and realized net revenue alongside clinical demand.
A molecule spanning dermatology, rheumatology and gastroenterology can support more comprehensive payer negotiations, but each indication may still face separate formulary rules and competing preferred products.
FDA’s 2025 efficacy-supplement calendar lists TREMFYA new-indication approval on March 20, 2025. Label expansion strengthens lifecycle management and creates a new pool of commercially eligible patients.
The July 2025 Canadian NOC covers moderately to severely active Crohn’s disease and new formulations, directly expanding both therapeutic scope and delivery options.
Current EMA information includes adult and pediatric plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease. A broad authorized label provides a platform for continued commercial growth subject to national reimbursement.
Guselkumab is commercially concentrated within Johnson & Johnson’s TREMFYA franchise, but the treatment markets it serves are highly competitive. Share is influenced by head-to-head evidence, class sequencing, dosing convenience, safety, physician familiarity, payer preference and the pace of label expansion.
Johnson & Johnson reported USD 5.155 billion in worldwide TREMFYA product sales in 2025, demonstrating substantial franchise scale that supports ongoing market access, evidence generation and lifecycle investment.
Across psoriasis, psoriatic arthritis and inflammatory bowel disease, guselkumab competes with other IL-23 agents, IL-17 therapies, TNF inhibitors and advanced oral treatments. Competition occurs at the treatment-pathway level rather than only molecule-to-molecule.
Recent Crohn’s-disease approvals, higher-strength presentations and pediatric expansion increase the franchise’s addressable market and help offset maturation in older indications.
Over the forecast period, leadership will depend on maintaining strong access while converting newer gastroenterology indications and delivery formats into sustained patient starts and persistence.
| Date | Development | Market Implication |
|---|---|---|
| March 2025 | FDA listed TREMFYA new-indication approval on March 20, 2025. | Expanded the U.S. addressable patient pool and strengthened lifecycle growth beyond established dermatology and rheumatology use. |
| July 2025 | Health Canada approved TREMFYA for moderately to severely active Crohn’s disease and added new presentations. | Broadened Canadian gastroenterology use and introduced additional subcutaneous dosing formats. |
| July 2025 | Singapore HSA approved 200 mg infusion and subcutaneous TREMFYA presentations with multiple immune-mediated indications. | Expanded presentation choice and regional commercialization in a high-value Asia-Pacific specialty market. |
| August 2025 | NICE published TA1094 for guselkumab in moderately to severely active ulcerative colitis. | Established a formal NHS health-technology-assessment pathway for reimbursed use in the United Kingdom. |
| March 2026 | EMA product information was updated with a broad indication set including pediatric plaque psoriasis from age six years. | Extended the European lifecycle and broadened the eligible population across age and specialty segments. |
The global guselkumab injection market market is estimated at USD 1.92 Bn in 2026 and is projected to reach USD 3.20 Bn by 2034, representing a 6.6% CAGR during 2026–2034.
Inflammatory-bowel indication expansion increases eligible patients and specialist prescribers.
New strengths, pediatric use and additional labels broaden the franchise beyond mature psoriasis demand.
Payer sequencing and national HTA decisions remain critical to converting approval into treatment volume.
Multiple biologic and oral classes require strong comparative evidence and differentiated convenience.
The Guselkumab Injection Market study is structured to support market sizing, segment planning, competitive assessment and geographic prioritization without exposing the detailed paid databook in the public overview.
2025 base year, 2026 estimate and 2034 forecast under a consistent 2026–2034 CAGR.
100 mg versus other presentation types and plaque psoriasis versus other applications.
Five regions with selective approval, HTA and product-sales signals.
TREMFYA franchise scale, class competition, label expansion and lifecycle positioning.
Indication growth, payer sequencing, therapeutic rivalry and specialty-channel adoption.
FDA, EMA, Health Canada, HSA and NICE developments shaping commercial reach.
Market sizing uses top-down reconciliation of addressable procedure, treatment or equipment pools with bottom-up company, product, channel and geography checks. Primary and secondary research are triangulated to test market boundaries, segment relationships and forecast assumptions.
Secondary research prioritizes regulators, government agencies, clinical or professional authorities, peer-reviewed literature, company filings and official product documentation. Company revenue is used only when it can be related to the target market without assigning unrelated portfolio sales to the market.
Forecasting considers adoption, replacement cycles, pricing, reimbursement, regulatory change, clinical practice, installed-base dynamics, competitive launches and geographic access. For a multi-indication biologic, total manufacturer product sales are treated as competitive context and are not automatically assigned to the target injection market. Market revenue is reconciled to the report’s narrower product and application boundary.
The market is valued at USD 1.80 Bn in 2025, estimated at USD 1.92 Bn in 2026 and projected to reach USD 3.20 Bn by 2034, representing a 6.6% CAGR during 2026–2034.
North America is the largest regional market in 2025, supported by U.S. franchise scale, high biologic penetration, broad specialty infrastructure and recent indication expansion.
Current regulatory labels across major markets include plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease, with age and presentation details varying by jurisdiction.
The 100 mg presentation has the established commercial base, while newer higher-strength and indication-specific formats are becoming more important in inflammatory bowel disease.
Recent indication expansion into inflammatory bowel disease is the strongest structural growth driver because it adds new patient populations and gastroenterology prescribers.
Guselkumab is marketed under the TREMFYA franchise by Johnson & Johnson entities including Janssen Biotech, Janssen-Cilag International and Janssen Inc.
The forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
FDA 2025 efficacy supplement approvals; Health Canada TREMFYA NOC; EMA Tremfya EPAR; Singapore HSA July 2025 approvals.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.
